nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadobutrol—Urine abnormality—Mitoxantrone—lymphatic system cancer	0.031	0.031	CcSEcCtD
Gadobutrol—Urine analysis abnormal—Mitoxantrone—lymphatic system cancer	0.0292	0.0292	CcSEcCtD
Gadobutrol—Aphasia—Carmustine—lymphatic system cancer	0.0285	0.0285	CcSEcCtD
Gadobutrol—Injection site pain—Carmustine—lymphatic system cancer	0.0226	0.0226	CcSEcCtD
Gadobutrol—Sweating increased—Fludarabine—lymphatic system cancer	0.0176	0.0176	CcSEcCtD
Gadobutrol—Vertigo—Mechlorethamine—lymphatic system cancer	0.0175	0.0175	CcSEcCtD
Gadobutrol—Abnormal vision—Carmustine—lymphatic system cancer	0.0161	0.0161	CcSEcCtD
Gadobutrol—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0159	0.0159	CcSEcCtD
Gadobutrol—Infection—Mechlorethamine—lymphatic system cancer	0.0158	0.0158	CcSEcCtD
Gadobutrol—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.0144	0.0144	CcSEcCtD
Gadobutrol—Visual impairment—Fludarabine—lymphatic system cancer	0.014	0.014	CcSEcCtD
Gadobutrol—Aphasia—Methotrexate—lymphatic system cancer	0.0132	0.0132	CcSEcCtD
Gadobutrol—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Gadobutrol—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Gadobutrol—Infection—Teniposide—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Gadobutrol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Gadobutrol—Convulsion—Fludarabine—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Gadobutrol—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Gadobutrol—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Gadobutrol—Sweating increased—Mitoxantrone—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Gadobutrol—Dyspnoea—Teniposide—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Gadobutrol—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Gadobutrol—Infection—Fludarabine—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Gadobutrol—Vomiting—Mechlorethamine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Gadobutrol—Rash—Mechlorethamine—lymphatic system cancer	0.01	0.01	CcSEcCtD
Gadobutrol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.01	0.01	CcSEcCtD
Gadobutrol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00995	0.00995	CcSEcCtD
Gadobutrol—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00957	0.00957	CcSEcCtD
Gadobutrol—Nausea—Mechlorethamine—lymphatic system cancer	0.00943	0.00943	CcSEcCtD
Gadobutrol—Abdominal pain—Teniposide—lymphatic system cancer	0.00926	0.00926	CcSEcCtD
Gadobutrol—Body temperature increased—Teniposide—lymphatic system cancer	0.00926	0.00926	CcSEcCtD
Gadobutrol—Paraesthesia—Fludarabine—lymphatic system cancer	0.00924	0.00924	CcSEcCtD
Gadobutrol—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00922	0.00922	CcSEcCtD
Gadobutrol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00917	0.00917	CcSEcCtD
Gadobutrol—Visual impairment—Carmustine—lymphatic system cancer	0.00893	0.00893	CcSEcCtD
Gadobutrol—Hypoaesthesia—Vincristine—lymphatic system cancer	0.0088	0.0088	CcSEcCtD
Gadobutrol—Pain—Fludarabine—lymphatic system cancer	0.0088	0.0088	CcSEcCtD
Gadobutrol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00863	0.00863	CcSEcCtD
Gadobutrol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00813	0.00813	CcSEcCtD
Gadobutrol—Diarrhoea—Teniposide—lymphatic system cancer	0.00801	0.00801	CcSEcCtD
Gadobutrol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00758	0.00758	CcSEcCtD
Gadobutrol—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00754	0.00754	CcSEcCtD
Gadobutrol—Infection—Bleomycin—lymphatic system cancer	0.0075	0.0075	CcSEcCtD
Gadobutrol—Vomiting—Teniposide—lymphatic system cancer	0.00744	0.00744	CcSEcCtD
Gadobutrol—Rash—Teniposide—lymphatic system cancer	0.00738	0.00738	CcSEcCtD
Gadobutrol—Dermatitis—Teniposide—lymphatic system cancer	0.00738	0.00738	CcSEcCtD
Gadobutrol—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00735	0.00735	CcSEcCtD
Gadobutrol—Headache—Teniposide—lymphatic system cancer	0.00733	0.00733	CcSEcCtD
Gadobutrol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00704	0.00704	CcSEcCtD
Gadobutrol—Convulsion—Carmustine—lymphatic system cancer	0.00699	0.00699	CcSEcCtD
Gadobutrol—Nausea—Teniposide—lymphatic system cancer	0.00695	0.00695	CcSEcCtD
Gadobutrol—Vertigo—Vincristine—lymphatic system cancer	0.00692	0.00692	CcSEcCtD
Gadobutrol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00677	0.00677	CcSEcCtD
Gadobutrol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00673	0.00673	CcSEcCtD
Gadobutrol—Convulsion—Vincristine—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Gadobutrol—Infection—Carmustine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Gadobutrol—Vomiting—Fludarabine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Gadobutrol—Convulsion—Mitoxantrone—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Gadobutrol—Rash—Fludarabine—lymphatic system cancer	0.00649	0.00649	CcSEcCtD
Gadobutrol—Dermatitis—Fludarabine—lymphatic system cancer	0.00648	0.00648	CcSEcCtD
Gadobutrol—Pain—Bleomycin—lymphatic system cancer	0.00645	0.00645	CcSEcCtD
Gadobutrol—Headache—Fludarabine—lymphatic system cancer	0.00645	0.00645	CcSEcCtD
Gadobutrol—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00641	0.00641	CcSEcCtD
Gadobutrol—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00629	0.00629	CcSEcCtD
Gadobutrol—Infection—Vincristine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Gadobutrol—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Gadobutrol—Nausea—Fludarabine—lymphatic system cancer	0.00611	0.00611	CcSEcCtD
Gadobutrol—Infection—Mitoxantrone—lymphatic system cancer	0.00608	0.00608	CcSEcCtD
Gadobutrol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00608	0.00608	CcSEcCtD
Gadobutrol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Gadobutrol—Insomnia—Carmustine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Gadobutrol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Gadobutrol—Paraesthesia—Carmustine—lymphatic system cancer	0.00591	0.00591	CcSEcCtD
Gadobutrol—Dyspnoea—Carmustine—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Gadobutrol—Insomnia—Vincristine—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Gadobutrol—Paraesthesia—Vincristine—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Gadobutrol—Pain—Carmustine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Gadobutrol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Gadobutrol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Gadobutrol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Gadobutrol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00539	0.00539	CcSEcCtD
Gadobutrol—Pain—Vincristine—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Gadobutrol—Pain—Mitoxantrone—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Gadobutrol—Abdominal pain—Carmustine—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Gadobutrol—Body temperature increased—Carmustine—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Gadobutrol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Gadobutrol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Gadobutrol—Abdominal pain—Vincristine—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Gadobutrol—Body temperature increased—Vincristine—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Gadobutrol—Hypersensitivity—Carmustine—lymphatic system cancer	0.00485	0.00485	CcSEcCtD
Gadobutrol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Gadobutrol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Gadobutrol—Vomiting—Bleomycin—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Gadobutrol—Rash—Bleomycin—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Gadobutrol—Dermatitis—Bleomycin—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Gadobutrol—Hypersensitivity—Vincristine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Gadobutrol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Gadobutrol—Diarrhoea—Carmustine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Gadobutrol—Nausea—Bleomycin—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Gadobutrol—Dizziness—Carmustine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Gadobutrol—Diarrhoea—Vincristine—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Gadobutrol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Gadobutrol—Vomiting—Carmustine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Gadobutrol—Dizziness—Vincristine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Gadobutrol—Rash—Carmustine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Gadobutrol—Dermatitis—Carmustine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Gadobutrol—Visual impairment—Methotrexate—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Gadobutrol—Headache—Carmustine—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Gadobutrol—Vomiting—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Gadobutrol—Rash—Vincristine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Gadobutrol—Dermatitis—Vincristine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Gadobutrol—Headache—Vincristine—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Gadobutrol—Nausea—Carmustine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Gadobutrol—Vomiting—Mitoxantrone—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Gadobutrol—Rash—Mitoxantrone—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Gadobutrol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Gadobutrol—Headache—Mitoxantrone—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Gadobutrol—Nausea—Vincristine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Gadobutrol—Dysgeusia—Methotrexate—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Gadobutrol—Nausea—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Gadobutrol—Vertigo—Methotrexate—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Gadobutrol—Convulsion—Methotrexate—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Gadobutrol—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Gadobutrol—Infection—Methotrexate—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Gadobutrol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Gadobutrol—Insomnia—Methotrexate—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Gadobutrol—Paraesthesia—Methotrexate—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Gadobutrol—Dyspnoea—Methotrexate—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Gadobutrol—Pain—Methotrexate—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Gadobutrol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Gadobutrol—Abdominal pain—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Gadobutrol—Body temperature increased—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Gadobutrol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Gadobutrol—Diarrhoea—Methotrexate—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Gadobutrol—Dizziness—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Gadobutrol—Vomiting—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Gadobutrol—Rash—Methotrexate—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Gadobutrol—Dermatitis—Methotrexate—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Gadobutrol—Headache—Methotrexate—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Gadobutrol—Nausea—Methotrexate—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
